stockrow
Friday 6 November 2026
Export IRON’s income statement to Excel — free account
Disc Medicine, Inc.
IRON Healthcare Biotechnology
- EPS
- +2.53%
- Free cash flow
- +7.83%
- Total debt
- +106.5%
Quarter to June 2026, against a year earlier
78.51
0.04
+0.05%
Follow IRON
Alert me
Disc Medicine, Inc. (IRON) P/E ratio
Disc Medicine, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| PBLS Parabilis Medicines, Inc. compare | n/m |
| IRON Disc Medicine, Inc. | n/m |
| IOVA Iovance Biotherapeutics, Inc. compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| DYN Dyne Therapeutics, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 10.0× |
| Biotechnology industry median | 10.3× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)